This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

ADCETRIS is an innovative, antibody-drug conjugate (ADC) that specifically targets human CD30+ tumour cells1,2

  • An ADC is a drug technology where drugs are linked to an antibody via a conditionally stable linker
  • ADCETRIS is an ADC consisting of 3 components:
    • The monoclonal antibody cAC10 specific for human CD30
    • The antimicrotubule agent monomethyl auristatin E (MMAE)
    • A protease-cleavable linker that covalently attaches MMAE to cAC10
  • ADCETRIS delivers the potent cytotoxic drug MMAE selectively into CD30+ expressing tumour cells, causing apoptosis1,2
ADC binding and uptake into tumour cell via CD30 receptor

ADC binding and uptake into tumour cell via CD30 receptor

Disruption of microtubule network by MMAE

Disruption of microtubule network by MMAE

Tumour cell apoptosis

Mechanism of Action

Pre-clinical data suggests that the antibody-drug conjugate selectively binds to CD30 on the cell surface, initiating internalisation of the antibody-drug conjugate-CD30 complex. This then migrates to the lysosomal compartment. Within the cell, MMAE is released via proteolytic cleavage. MMAE binds to tubulin and disrupts the microtubule network, inducing cell cycle arrest and resulting in apoptotic death.1


Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.